DESVENLAFAXINE TABLET (EXTENDED-RELEASE)
Country: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
06-02-2023
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
DESVENLAFAXINE
Fáanlegur frá:
SANIS HEALTH INC
ATC númer:
N06AX23
INN (Alþjóðlegt nafn):
DESVENLAFAXINE
Skammtar:
100MG
Lyfjaform:
TABLET (EXTENDED-RELEASE)
Samsetning:
DESVENLAFAXINE 100MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
15G/50G
Gerð lyfseðils:
Prescription
Vörulýsing:
Active ingredient group (AIG) number: 0152509002; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
2023-02-06
Vara einkenni
_ _
_DESVENLAFAXINE PRODUCT MONOGRAPH PAGE 1 OF 51 _
PRODUCT MONOGRAPH
PR
DESVENLAFAXINE
Desvenlafaxine Extended-Release Tablets
Extended-release tablets, 50 mg and 100 mg Desvenlafaxine, Oral
Antidepressant
SANIS HEALTH INC.
1 PRESIDENT'S CHOICE CIRCLE
BRAMPTON, ONTARIO
L6Y 5S5
SUBMISSION CONTROL NUMBER: 270697
DATE OF
PREPARATION:
FEB
06, 2023
_ _
_DESVENLAFAXINE PRODUCT MONOGRAPH PAGE 2 OF 51 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
......................................................... 3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
...........................................................................................................
4
WARNINGS AND PRECAUTIONS
.........................................................................................
4
ADVERSE REACTIONS
.........................................................................................................
11
DRUG INTERACTIONS
.........................................................................................................
21
DOSAGE AND ADMINISTRATION
.....................................................................................
24
OVERDOSAGE
........................................................................................................................
26
ACTION AND CLINICAL PHARMACOLOGY
....................................................................
28
STORAGE AND STABILITY
.................................................................................................
31
SPECIAL HANDLING INSTRUCTIONS
...............................................................................
31
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 31
PART II: SCIENTIFIC INFORMATION
...............................................................................
33
P
Lestu allt skjalið
